# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Proposed Single Technology Appraisal

### Omalizumab for previously treated chronic spontaneous urticaria

### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
<ul> <li>Novartis Pharmaceuticals</li> </ul>	Allied Health Professionals Federation
(omalizumab)	<ul> <li>Board of Community Health Councils in Wales</li> </ul>
Patient/carer groups	British National Formulary
Action Against Allergy	Care Quality Commission
Action for Children	Commissioning Support Appraisals
Action for Sick Children	Service
Afiya Trust	Department of Health, Social Services
Allergy UK	and Public Safety for Northern Ireland
Black Health Agency	Healthcare Improvement Scotland
Changing faces	Medicines and Healthcare products
Children's Society	Regulatory Agency
Equalities National Council	National Association of Primary Care
Let's Face It	National Pharmacy Association
Muslim Council of Britain	NHS Alliance
Muslim Health Network	NHS Commercial Medicines Unit
<ul> <li>National Children's Bureau</li> </ul>	NHS Confederation
National Parent Partnership Network	Scottish Medicines Consortium
Skin Care Campaign	
South Asian Health Foundation	Comparator manufacturers
Specialised Healthcare Alliance	Accord Healthcare (methotrexate)
WellChild	Amco (methotrexate)
	Crescent Pharma (sulfasalazine)
Professional groups	Dexcel (ciclosporin)
British Association of Dermatologists	Hameln Pharmaceuticals
British Contact Dermatitis Society	(methotrexate)
British Dermatological Nursing Group	Hospira UK (methotrexate)
British Geriatrics Society	Medac GmbH (methotrexate)
British Skin Foundation	Mylan UK (sulfasalazine)
British Society for Paediatric	Novartis (ciclosporin)
Dermatology	Orion Pharma UK (methotrexate)
Primary Care Dermatology Society	Pfizer (methotrexate, sulfasalazine)
Royal College of General Practitioners	Rosemont Pharmaceuticals
Royal College of Nursing	(sulfasalazine)
• Royal College of Paediatrics and Child	Sandoz (methotrexate, sulfasalazine)

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of omalizumab for previously treated spontaneous urticaria

Consultees	Commentators (no right to submit or appeal)
Health	Teva UK (ciclosporin, methotrexate,
<ul> <li>Royal College of Pathologists</li> </ul>	sulfasalazine)
<ul> <li>Royal College of Physicians</li> </ul>	<ul> <li>Wockhardt UK (methotrexate)</li> </ul>
<ul> <li>Royal Pharmaceutical Society</li> </ul>	
<ul> <li>Royal Society of Medicine</li> </ul>	Relevant research groups
United Kingdom Clinical Pharmacy	British Epidermo-Epidemiology Society
Association	<ul> <li>Centre of Evidence-based Dermatology, University of Nottingham</li> </ul>
Othoro	Cochrane Skin Group
Others <ul> <li>Department of Health</li> </ul>	<ul> <li>Health Research Authority</li> </ul>
<ul> <li>NHS England</li> </ul>	MRC Clinical Trials Unit
<ul> <li>NHS East Staffordshire CCG</li> </ul>	<ul> <li>National Institute for Health Research</li> </ul>
<ul> <li>NHS Rushcliffe CCG</li> </ul>	<ul> <li>Research Institute for the Care of Older</li> </ul>
<ul> <li>Welsh Government</li> </ul>	People
• Weish Government	<ul> <li>Skin Research Centre, University of</li> </ul>
	Leeds
	Skin Treatment & Research Trust
	Evidence Review Group
	Evidence Review Group tbc
	National Institute for Health Research
	Health Technology Assessment
	Programme
	Associated Guideline Groups
	National Clinical Guidelines Centre
	Associated Public Health Groups
	Public Health England
	Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

#### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

## **Definitions:**

### <u>Consultees</u>

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### **Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Care Excellence Provisional matrix for the proposed technology appraisal of omalizumab for previously treated spontaneous urticaria Issue date: November 2013

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.